Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes

Pharmacology, Toxicology and Pharmaceutical Science

• Lipid 100%
• Rosiglitazone 100%
• Insulin Glargine 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Hemoglobin A1c 33%
• Biological Marker 22%
• Isoprostane Derivative 22%
• Glucose 22%
• Randomized Clinical Trial 11%
• Sulfonylurea 11%
• Add on Therapy 11%
• Metformin 11%
• Low Density Lipoprotein Cholesterol 11%
• High Density Lipoprotein Cholesterol 11%
• Insulin Deficiency 11%
• Antidiabetic Agent 11%
• Inflammation 11%
• Insulin 11%

Biochemistry, Genetics and Molecular Biology

• Lipid 100%
• Glycemic Control 100%
• Rosiglitazone 100%
• Insulin Glargine 100%
• Plasminogen Activator Inhibitor-1 22%
• Isoprostane 22%
• Glucose 22%
• Insulin 22%
• Reduction (Chemistry) 11%
• Randomized Clinical Trial 11%
• Dose 11%
• Weight 11%
• Decision Making 11%
• Low Density Lipoprotein Cholesterol Level 11%
• Total Cholesterol Level 11%
• High Density Lipoprotein Cholesterol Level 11%
• Sulfonylurea 11%
• Blood Plasma 11%

Immunology and Microbiology

• Glycemic Control 100%
• Isoprostane Derivative 50%
• Inflammation 25%
• Blood Plasma 25%
• Reduction (Chemistry) 25%
• Dose 25%
• Weight 25%
• Decision Making 25%
• High Density Lipoprotein Cholesterol Level 25%
• Low Density Lipoprotein Cholesterol Level 25%
• Total Cholesterol Level 25%